B&L invests in presbyopia

Article

Bausch & Lomb has made an equity investment in AcuFocus.

Bausch & Lomb has made an equity investment in - and secures an exclusive option to purchase - AcuFocus, a privately held company in California, USA.

AcuFocus is developing a corneal inlay, the ACI 7000, for the treatment of presbyopia. The inlay is implanted in the cornea under a LASIK flap and incorporates technology that increases a patient's depth of field, thereby improving near vision. The procedure involves no tissue removal and does not permanently alter the cornea, so pre-implant vision can be restored should the inlay be removed. Terms of the agreement were not disclosed.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.